- Home
- AMPY vs IKT Comparison
AMPY vs IKT Comparison
Compare AMPY & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMPY | IKT |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.1M | 181.9M |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMPY | IKT |
|---|---|---|
| Price | $4.59 | $1.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $11.00 | $4.00 |
| AVG Volume (30 Days) | ★ 643.6K | 543.2K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $275,827,100.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.27 | $1.33 |
| 52 Week High | $6.62 | $4.20 |
Technical Indicators
Market Signals| Indicator | AMPY | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 62.92 |
| Support Level | $4.53 | $1.52 |
| Resistance Level | $4.71 | $1.67 |
| Average True Range (ATR) | 0.22 | 0.10 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 4.69 | 90.77 |
Price Performance
Historical ComparisonAbout AMPY Amplify Energy Corp.
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The company's oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.